MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$236,718K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Proceeds from sales and maturiti...
Amortization of intangible asset...
Others
Negative Cash Flow Breakdown
Repurchase of common stock
Purchases of marketable securiti...
Prepaid expenses and other asset...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
229,913
150,049
-141,591
175,225
Share-based compensation
17,698
16,637
16,571
12,160
Depreciation and amortization
4,455
4,221
3,304
2,658
Amortization of intangible assets
29,512
29,512
23,376
17,762
Amortization of debt discount
2,254
2,245
1,950
1,858
Accretion of premium on marketable securities, net
602
30
96
357
Realized loss on marketable securities
-28
-
244
-47
Loss on disposal of equipment
-76
-
-2,621
0
Contingent liability fair value measurement adjustment
-
-
0
-
Lease payments recognized
-215
-214
-271
-170
Induced conversion expense related to 2027 and 2028 convertible notes
-
-
5,477
-
Deferred income taxes
-907
-3,428
16,768
-27,354
Acquired in-process research and development expense
-
-
284,887
-
Impairment of intangible asset
-
-
48,700
-
Accounts receivable, net and contract assets
-2,162
19,547
90,483
29,696
Inventories
-18,332
-27,379
-18,781
1,101
Prepaid expenses and other assets
41,148
9,108
-28,424
20,319
Accounts payable and accrued expenses
-22,911
-24,922
33,849
-7,164
Net cash provided by operating activities
240,891
180,078
219,029
178,597
Purchases of marketable securities
111,759
8,846
0
4,956
Proceeds from sales and maturities of marketable securities
-
-
722,248
-
Acquisition of business, net of cash acquired
-
-
725,965
-
Proceeds from sales and maturities of marketable securities
53,269
-439,873
-
209,595
Acquisition of in-process research and development, net of cash acquired
-
-
287,771
-
Proceeds from working capital adjustments on acquisition
0
710
-
-
Purchases of property and equipment
4,173
3,741
1,427
3,030
Net cash used in investing activities
-62,663
-2,877
-741,788
201,609
Repayments of convertible notes-A2024Convertible Notes
-
-
0
-
Repayments of convertible notes-A0.25Convertible Senior Notes Due2027
-
-
595,425
-
Repayments of convertible notes-A1.00Convertible Senior Notes Due2028
-
-
250,001
-
Proceeds from convertible debt-A0.00Convertible Senior Notes Due2031
-
-
735,000
-
Proceeds from convertible debt-A0.875Convertible Senior Notes Due2032
-
-
735,000
-
Payment for the induced conversion of 2027 and 2028 convertible notes
-
-
5,477
-
Premium on repayment of convertible notes settled in cash-A0.25Convertible Senior Notes Due2027
-
-
78,132
-
Premium on repayment of convertible notes settled in cash-A1.00Convertible Senior Notes Due2028
-
-
89,833
-
Purchase of capped calls on 2031 convertible notes-A0.00Convertible Senior Notes Due2031
-
-
104,025
-
Purchase of capped calls on 2031 convertible notes-A0.875Convertible Senior Notes Due2032
-
-
106,800
-
Payment of debt issuance cost
-
-
4,938
-
Repurchase of common stock
332,729
-
0
38,883
Taxes paid related to net share settlement, net of proceeds from issuance of common stock under equity incentive plans
-
1,613
-
-
Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement
4,865
-
4,146
16,481
Net cash used in financing activities
-326,251
-1,613
239,515
-22,402
Net increase (decrease) in cash and cash equivalents
-148,023
175,588
-283,244
357,804
Cash and cash equivalents at beginning of period
312,009
136,421
419,665
115,850
Cash and cash equivalents at end of period
163,986
-
-
-
Cash and cash equivalents
163,138
-
-
-
Restricted cash
848
-
-
-
Total cash, cash equivalents and restricted cash
163,986
312,009
136,421
419,665
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$229,913K
(-18.83%↓ Y/Y)
Amortization of intangible
assets
$29,512K
(-16.92%↓ Y/Y)
Inventories
-$18,332K
(-221.20%↓ Y/Y)
Share-based compensation
$17,698K
(-22.49%↓ Y/Y)
Depreciation and
amortization
$4,455K
(-17.91%↓ Y/Y)
Amortization of debt discount
$2,254K
(-39.05%↓ Y/Y)
Accounts receivable, net
and contract assets
-$2,162K
(-127.42%↓ Y/Y)
Deferred income taxes
-$907K
(-109.11%↓ Y/Y)
Lease payments
recognized
-$215K
(57.84%↑ Y/Y)
Loss on disposal of
equipment
-$76K
Realized loss on
marketable securities
-$28K
(-7.69%↓ Y/Y)
Net cash provided by
operating activities
$240,891K
(-5.14%↓ Y/Y)
Canceled cashflow
$64,661K
Net increase
(decrease) in cash and cash...
-$148,023K
(-174.17%↓ Y/Y)
Canceled cashflow
$240,891K
Proceeds from issuance of
common stock under...
$4,865K
(304.74%↑ Y/Y)
Proceeds from sales and
maturities of marketable...
$53,269K
(-77.74%↓ Y/Y)
Prepaid expenses and
other assets
$41,148K
(0.21%↑ Y/Y)
Accounts payable and
accrued expenses
-$22,911K
(-11.90%↓ Y/Y)
Accretion of premium on
marketable securities, net
$602K
(-78.83%↓ Y/Y)
Net cash used in
financing activities
-$326,251K
(-7.93%↓ Y/Y)
Canceled cashflow
$4,865K
Net cash used in
investing activities
-$62,663K
(-1012.23%↓ Y/Y)
Canceled cashflow
$53,269K
Repurchase of common stock
$332,729K
(9.63%↑ Y/Y)
Purchases of marketable
securities
$111,759K
(-53.89%↓ Y/Y)
Purchases of property and
equipment
$4,173K
(66.06%↑ Y/Y)
Buy us a coffee
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)